Everolimus after failure of sorafenib did not improve survival of patients with advanced hepatocellular carcinoma
(dailyRx News) Even when new medications show a lot of promise in the early stages of testing, they don’t always prove to work so well in later stages of testing. For certain liver cancer patients, everolimus (Afinitor) may be less effective against tumors than previously thought.
In a recent trial, everolimus did not boost survival compared to placebo (mock medication) in patients with an advanced form of liver cancer.
Read more from RxWiki HERE.